Biotech Earnings Calendar

: Drug: NRX-0305. Indication: intracranial models of melanoma brain metastasis and primary glioma. Timeline: 2026-04-21. Nurix will present preclinical data on NRX-0305 showing robust efficacy in intracranial models of melanoma brain metastasis and primary glioma at the AACR 2026 Annual Meeting (April 21, 2026).

: An interim analysis will be performed in the third quarter of 2026 when 24 subjects complete the 8-month follow-up visit post-OCU410ST treatment.

: Drug: pumitamig (BNT327). Indication: cancer. Timeline: next year. BioNTech is on course to report Phase III results for pumitamig (BNT327), a PD-L1xVEGF bispecific, next year.

: The U.S. FDA is expected to make a decision on the supplemental Biologics License Application (sBLA) for Dupixent in children aged 2 to 11 years with CSU by April 2026.

: Drug: EKTERLY (sebetralstat). Indication: Hereditary angioedema (HAE), ages 2–11. Timeline: third quarter of 2026. KalVista expects to file a U.S. New Drug Application (NDA) for EKTERLY (sebetralstat) to expand use to children aged 2–11 in the third quarter of 2026, with a launch anticipated in 2027.

: The Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy is expected to deliver top-line results in 2026, following the approval of PsyLabs’ psilocybin product for clinical use.

: OKYO Pharma will present data from a Phase 2a clinical trial of urcosimod at the ARVO 2026 Annual Meeting, highlighting significant pain reduction and quality-of-life improvements in NCP patients.